查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1839061

細胞治療技術市場：按產品、治療類型、生產流程、給藥方式、應用和最終用戶分類－2025-2032年全球預測

Cell Therapy Technologies Market by Offering, Therapy Type, Manufacturing Process, Delivery Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，細胞治療技術市場將成長至 136.8 億美元，複合年成長率為 14.41%。

主要市場統計數據
基準年 2024 46.6億美元
預計年份：2025年 52.9億美元
預測年份：2032年 136.8億美元
複合年成長率 (%) 14.41%

一個權威的框架，用於說明科學突破、製造現實和商業性動態如何融合，從而製定細胞療法商業化的議程。

細胞療法正從實驗性干預發展成為一種結構化的臨床和商業性模式，挑戰傳統的製藥模式。過去十年，細胞來源、基因改造和自動化生產的科學進步，與新的監管管道和不斷擴大的臨床證據相融合，拓展了細胞療法的適應症範圍。這一發展進程是由當前的生態系統推動的，該生態系統認知到，僅靠技術創新並不能保證應用；可生產性、品質系統、報銷策略以及可靠的供應鏈組裝能力同樣至關重要。

在取得突破性的臨床里程碑之後，相關人員目前關注的重點是流程的可重複性、交貨成本以及確保產品可追溯性和患者安全的資料系統整合。投資者和策略合作夥伴正在評估該平台在不同治療方法類型、給藥方式和終端用戶環境中的適用性。因此，業界正朝著模組化解決方案的方向發展，將耗材、專用設備和軟體服務結合，以縮短週期時間並提高可重複性。這種應用為後續分析奠定了基礎，凸顯了科學、製造、監管和商業領域之間的相互依存關係，強調了跨職能規劃的必要性，以將技術前景轉化為對患者的持續影響。

自動化、資料管理和治療方式的進步如何重塑細胞治療生態系統的生產模式和商業策略？

細胞治療領域正從多個維度發生變革，重新定義競爭優勢和營運重點。向臨床階段的過渡推動生產流程從單一地點、小批量生產轉向可擴展、標準化的生產模式，強調自動化和封閉式系統。這種轉變降低了操作人員的差異性，加快了產品上市速度，同時也讓人們更加關注設備的互通性和耗材的標準化。同時，數據管理層正逐漸成為一項策略資產。能夠實現批次級追溯、品管分析和法規文件編制的軟體和服務，對於提升營運韌性至關重要。

在治療方面，從本土研發的第一代產品轉向異體和基因工程治療方法正在重塑供應鏈設計和商業性思維。異體移植方法提升了上游供體來源和庫存策略的重要性，而基因修飾平台則拓展了細胞治療生產商和分子生物學供應商之間的聯繫。臨床試驗和生產設施的區域分散化也是一個變革性趨勢，其促進因素包括人才取得、成本差異和監管環境。總而言之，這些轉變標誌著一個日趨成熟的行業，該行業必須在科學創新、可重複生產和商業性規模化之間取得平衡，以確保更廣泛的患者群體能夠獲得治療。

2025 年前美國關稅政策演變的影響，以及供應鏈策略和資本計畫應如何調整以降低累積風險。

預計2025年美國關稅政策的變化將帶來多重地緣政治和成本風險，相關人員必須積極應對。影響進口設備、專用耗材和原料的關稅可能導致資本計劃延期和單劑製造成本上升，即使企業試圖消化短期影響。要更理解其累積影響，最好透過情境規劃，將投入品採購、製造外包關係、庫存策略等因素納入考量。在受關稅影響的情況下，擁有多元化供應商網路和本土生產選擇的企業將更具優勢，而依賴單一進口管道的企業則可能面臨營運中斷。

監管和採購團隊應評估供應商合約中的不可抗力條款和價格彈性，而商務負責人應更新報銷模式以反映潛在的成本上漲。策略因應措施包括加速國內供應商的資質認證，採用模組化生產以減少對大規模進口組件的依賴，以及投資於降低單次用藥耗材強度的技術。同時，企業發展部門應重新評估跨境夥伴關係，並考慮選擇能減輕關稅影響的區域性製造地。將關稅情境納入資本規劃和供應商風險評估，有助於企業維持計劃進度，並保護利潤免受政策突變的影響。

全面的細分洞察揭示了細胞治療價值鏈中策略重點是如何透過產品、治療類型、生產流程、給藥方式、應用和最終用戶來確定的。

我們的分析揭示了能夠最有效地加速您專案進展的投資和營運重點。耗材支援日常細胞處理和試劑一致性，反應器和細胞分析儀等設備可實現規模化和流程控制，而專注於資料管理和品管的軟體和服務則為可追溯性和法規遵循提供了數位化基礎。這些層面相互依存；設備的選擇會影響您的耗材用量，而資料系統對於檢驗製程效能至關重要。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對固態腫瘤抗藥性機制的同種異體CAR-T細胞療法的研究進展
  • 創新非病毒基因組編輯平台，實現可擴展的細胞治療生產流程
  • 現成的自然殺手細胞療法的出現，可快速產生免疫腫瘤治療反應
  • 在細胞治療規模化生產過程中，整合自動化封閉式反應器以降低生產成本
  • FDA和EMA之間的監管協調舉措旨在加速細胞療法的市場核准
  • 利用人工智慧建模預測細胞生長和療效結果
  • 針對罕見癌症抗原的個人化T細胞受體修飾治療方法的開發
  • 利用誘導性多功能幹細胞進行同種異體再生醫學治療神經退化性疾病
  • 透過生技公司與合約研發生產力機構（CDMO）之間的策略聯盟，加強全球細胞療法供應鏈。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 細胞治療技術市場（依產品/服務分類）

  • 消耗品
  • 裝置
    • 反應器
    • 細胞分析儀
  • 軟體和服務
    • 資料管理
    • 品管

第9章 依治療類型分類的細胞治療技術市場

  • 異體細胞療法
    • 樹突狀細胞
    • 誘導性多功能細胞
    • 自然殺手細胞
  • 自體細胞療法
    • 造血幹細胞
    • 間質幹細胞
    • T細胞
  • 基因改造細胞療法
    • CAR-T細胞療法
    • TCR（T細胞受體）療法

第10章 依製造流程分類的細胞治療技術市場

  • 細胞培養
    • 2D文化系統
    • 3D培養系統
  • 細胞增殖
    • 依附文化
    • 懸浮培養
  • 細胞分離
    • 螢光活化細胞分選
    • 磁激活細胞分選

第11章 細胞治療技術市場：依給藥方式分類

  • Ex vivo
  • In vivo

第12章 細胞治療技術市場：依應用領域分類

  • 心血管疾病
    • 缺血性心臟疾病
    • 周邊動脈疾病
  • 肌肉骨骼疾病
    • 骨關節炎
    • 類風濕性關節炎
  • 神經退化性疾病
    • 阿茲海默症
    • 帕金森氏症
  • 瘤
    • 血癌
    • 固態腫瘤
      • 乳癌
      • 肺癌
      • 攝護腺癌

第13章 依最終用戶分類的細胞治療技術市場

  • 生物製藥公司
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所
    • 政府研究中心
    • 大學學術機構

第14章 細胞治療技術市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 細胞治療技術市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國細胞治療技術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Allogene Therapeutics Inc.
    • Atara BIoTherapeutics, Inc.
    • Century Therapeutics, Inc.
    • Charles River Laboratories International, Inc.
    • Gamida Cell Ltd.
    • GE HealthCare
    • Gilead Sciences, Inc.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Sartorius AG
    • Takara Bio Inc.
    • Takeda Pharmaceutical Company Limited
    • Thermo Fisher Scientific Inc.
    • Vericel Corporation
Product Code: MRR-034230D3E636

The Cell Therapy Technologies Market is projected to grow by USD 13.68 billion at a CAGR of 14.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.66 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2032] USD 13.68 billion
CAGR (%) 14.41%

An authoritative framing of how scientific breakthroughs, manufacturing realities, and commercial dynamics converge to set the agenda for cell therapy commercialization

Cell therapies are evolving from experimental interventions into structured clinical and commercial paradigms that challenge conventional pharmaceutical models. Over the past decade, scientific advances in cell sourcing, genetic modification, and automated manufacturing have converged with new regulatory pathways and expanding clinical evidence to broaden the set of indications addressed by cell-based interventions. This introduction frames the current ecosystem by acknowledging that technical innovation alone does not guarantee adoption; equally important are manufacturability, quality systems, reimbursement strategy, and the ability to scale supply chains reliably.

In the wake of transformative clinical milestones, stakeholders now focus on the repeatability of processes, cost-to-deliver, and integration of data systems that ensure product traceability and patient safety. Investors and strategic partners increasingly assess platform applicability across therapy types, delivery methods, and end-user contexts. The industry is therefore transitioning toward modular solutions that combine consumables, specialized equipment, and software-enabled services to reduce cycle times and improve reproducibility. This introduction sets the scene for subsequent analysis by highlighting interdependencies across scientific, manufacturing, regulatory, and commercial domains, and underscores the imperative for cross-functional planning to convert technological promise into durable patient impact.

How advances in automation, data management, and therapeutic modality evolution are reshaping manufacturing models and commercial strategies across the cell therapy ecosystem

The landscape for cell therapies is shifting along multiple axes that will redefine competitive advantage and operational priorities. Clinical translation is driving a move from single-center, small-batch workflows toward scalable, standardized manufacturing approaches that emphasize automation and closed systems. This shift reduces operator variability and shortens time-to-release, but it also concentrates attention on equipment interoperability and consumable standardization. Concurrently, data management layers are emerging as strategic assets: software and services that enable batch-level traceability, quality control analytics, and regulatory-ready documentation are becoming essential to operational resilience.

Therapeutically, the sequence from autologous first-generation products to allogeneic and gene-modified modalities is reshaping supply chain design and commercial thinking. Allogeneic approaches increase the importance of upstream donor sourcing and inventory strategies, while gene-modified platforms expand the interface between cell therapy manufacturers and molecular biology suppliers. Geographic diversification of clinical trials and manufacturing facilities is another transformative trend, motivated by talent access, cost differentials, and regulatory landscapes. Taken together, these shifts signal a maturing industry that must balance scientific innovation with reproducible manufacturing and commercial scalability to unlock broader patient access.

Scenario-based implications of evolving United States tariffs for 2025 and how supply chain strategies and capital planning must adapt to mitigate cumulative risk

Anticipated changes in United States tariff policy for 2025 introduce a layer of geopolitical and cost risk that stakeholders must manage proactively. Tariffs that affect imported equipment, specialized consumables, or raw materials can translate into delayed capital projects and higher per-dose manufacturing costs, even when organizations seek to absorb short-term impacts. The cumulative effect is best understood through scenario planning that considers input sourcing, contract manufacturing relationships, and inventory strategies. In tariffs-impacted scenarios, firms with diversified supplier networks and onshore manufacturing options will be favored, while those reliant on single-source import channels may face operational disruptions.

Regulatory and procurement teams should evaluate supplier contracts for force majeure and pricing flexibility, while commercial leads should update reimbursement models to reflect potential cost inflation. Strategic responses include accelerating qualification of domestic suppliers, modularizing manufacturing to reduce reliance on large imported assemblies, and investing in technologies that lower consumable intensity per dose. In parallel, corporate development functions should reassess cross-border partnerships and consider regional manufacturing hubs that mitigate tariff exposure. By integrating tariff scenarios into capital planning and supplier risk assessments, organizations can preserve project timelines and protect margins against abrupt policy shifts.

Comprehensive segmentation insights showing how offerings, therapy types, manufacturing processes, delivery methods, applications, and end users define strategic priorities across the cell therapy value chain

Segmentation-driven insight reveals where investments and operational focus will most effectively accelerate program advancement. Based on offering, it is essential to recognize how consumables, equipment, and software and services play complementary roles: consumables underpin day-to-day cell handling and reagent consistency, equipment such as bioreactors and cell analyzers enable scale and process control, and software and services focused on data management and quality control provide the digital backbone for traceability and regulatory compliance. These layers are interdependent; equipment choices influence consumable footprints, and data systems are necessary to validate process performance.

Based on therapy type, differentiation between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy determines manufacturing architecture. Allogeneic modalities, including dendritic cells, induced pluripotent stem cells, and natural killer cells, prioritize donor sourcing and batch banking approaches. Autologous therapies, such as hematopoietic stem cells, mesenchymal stem cells, and T-cells, demand patient-matched logistics and agile closed systems. Gene-modified treatments, exemplified by CAR-T and TCR therapies, layer genetic engineering steps that require integrated vector production and stringent quality control.

Based on manufacturing process, attention to cell culture, expansion, and separation illuminates capital and skills requirements. Cell culture systems that include 2D and 3D platforms drive upstream process design, while cell expansion choices between adherent and suspension culture affect scale economics. Cell separation technologies such as fluorescence-activated cell sorting and magnetic-activated cell sorting underpin purity and potency metrics. Based on delivery method, the ex vivo and in vivo dichotomy shapes cold-chain needs, administration logistics, and clinical workflow integration. Based on application, therapeutic focus across cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology informs target product profiles and clinical development pathways, with further granularity across ischemic heart disease, peripheral artery disease, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, Parkinson's disease, hematological cancer, and a range of solid tumors including breast, lung, and prostate cancers influencing clinical endpoint selection. Based on end user, the ecosystem of biopharmaceutical companies, hospitals, and research institutes-where hospitals may be private or public and research institutes include government research centers and university academics-creates diverse procurement cycles and operational capabilities that must be matched by suppliers seeking commercial traction.

How regional regulatory nuance, clinical networks, and infrastructure strengths across the Americas, Europe Middle East & Africa, and Asia-Pacific inform where to invest and localize capabilities

Regional context materially affects strategic choices for development, manufacturing, and market access. In the Americas, advanced clinical trial networks, established reimbursement mechanisms for advanced therapies, and a concentration of venture and corporate capital support rapid translation, but stakeholders must also navigate complex payer dynamics and regional regulatory nuance. Europe, Middle East & Africa presents heterogeneous regulatory regimes and reimbursement environments where centralized approvals can coexist with country-level access barriers, creating an imperative for localized engagement and adaptive pricing strategies. In Asia-Pacific, growing government support, investments in manufacturing infrastructure, and talent development are accelerating regional capability, though intellectual property considerations and local regulatory maturity vary widely.

Given these differences, companies should align site selection, clinical trial designs, and partnership models to regional strengths. Manufacturing footprints can be hybrid: using near-market capacity in the Americas for rapid commercial launches, leveraging EMEA partners for regulatory alignment and access to diverse patient populations, and establishing scaled capabilities in Asia-Pacific to benefit from growing clinical demand and cost efficiencies. Cross-border coordination of regulatory submissions, supply chain logistics, and commercial strategy will be critical to sustain global programs and minimize time-to-patient across jurisdictions.

Patterns in company strategies and partnership models showing how integrated capabilities, outsourcing decisions, and regulatory engagement shape competitive advantage in cell therapy

Insights into company behavior reveal patterns that will influence competitive dynamics and partnership opportunities. Leading organizations increasingly combine in-house capabilities with strategic outsourcing to balance control and speed; they retain core competencies in process development and quality assurance while partnering for vector production, fill-finish, or specialized analytics. Companies that invest early in modular, automation-friendly equipment and harmonized data systems achieve faster tech transfer and reduce variability across sites. This capability set also attracts collaborators that seek predictable scale-up pathways.

Smaller innovators tend to concentrate on platform differentiation and clinical proof-of-concept while relying on contract development and manufacturing organizations for production. Strategic acquirers and corporate venture arms favor platforms that de-risk manufacturing or improve cost of goods, making manufacturing-focused technologies and quality automation attractive targets. Across the ecosystem, suppliers that offer integrated solutions-combining consumables, validated equipment, and quality-ready software-are best positioned to enter long-term supply agreements. Lastly, companies emphasizing regulatory engagement and early payer dialogue demonstrate higher resilience in navigating post-approval access challenges.

Actionable strategic priorities to fortify manufacturing resilience, accelerate market access, and de-risk commercialization through targeted investments and partnerships

Industry leaders must translate insight into prioritized actions that reduce operational risk and accelerate commercialization. First, align capital investments with modular automation and validated equipment that enable replication across sites, thereby lowering tech transfer friction and supporting rapid scale-up. Second, formalize supplier diversification strategies and qualify domestic alternatives for critical consumables and equipment subcomponents to mitigate geopolitical and tariff-related disruption. Third, invest in robust data management and quality control systems that support batch release, regulatory submissions, and traceability across decentralized manufacturing networks.

Additionally, pursue strategic partnerships that close capability gaps without diluting core intellectual property, and coordinate early with payers and regulatory authorities to define evidentiary pathways that reflect real-world use cases. Prioritize workforce development programs that upskill operators and quality professionals in cell therapy-specific practices, and create cross-functional commercialization playbooks that tie clinical development milestones to manufacturing scale triggers. Finally, adopt scenario-based financial planning that models supply chain shocks, reimbursement variability, and capital deployment options so that leadership teams can make decisive moves under uncertainty.

An explainable and reproducible methodology integrating executive interviews, secondary evidence, and cross-validation to underpin actionable recommendations for cell therapy stakeholders

The research methodology underpinning this analysis blends primary engagement with subject-matter experts and structured secondary synthesis to ensure both depth and practical relevance. Primary inputs include in-depth interviews with senior manufacturing leaders, quality assurance executives, clinical operations heads, and commercial strategy professionals from developers, contract manufacturers, and hospital systems. These conversations probe operational constraints, technology adoption drivers, and decision criteria that shape supplier selection. Secondary sources comprise scientific literature, regulatory guidance documents, company technical disclosures, and industry white papers used to validate technology feasibility and regulatory pathways.

Data triangulation reconciles qualitative insights with documented process descriptions and public regulatory filings. The approach emphasizes reproducibility by cross-checking vendor claims against independent technical evaluations and by capturing divergent viewpoints where consensus does not exist. Quality assurance workflows include peer review by analysts with process engineering and regulatory experience, and sensitivity checks that surface assumptions underpinning strategic recommendations. Where appropriate, limitations and potential bias are noted, and recommendations carry clear implementation considerations so that decision-makers can adapt findings to their specific organizational context.

A strategic synthesis demonstrating that durable success in cell therapy requires the integration of scientific innovation, manufacturing discipline, and market-aligned commercialization planning

In conclusion, the cell therapy sector stands at an inflection point where scientific maturity is converging with operational discipline and commercial pragmatism. The path to broader patient access requires more than therapeutic novelty; it demands manufacturing reproducibility, digitally enabled quality systems, and supply chains designed to withstand geopolitical and policy shifts. Stakeholders that synchronize investments in consumables, equipment, and software with therapy-specific manufacturing choices will realize faster and more reliable program progression.

Moreover, regional strategy, company-level partnership models, and proactive payer engagement will determine the pace of adoption across indications. By emphasizing modular automation, diversified sourcing, and data-driven quality control, organizations can reduce execution risk and improve the odds of sustainable commercialization. The cumulative message is clear: success in cell therapy will be driven by integrative strategies that connect scientific innovation to operational excellence and market-focused commercialization plans. This conclusion should guide leadership teams as they prioritize near-term investments and longer-term capability building.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in allogeneic CAR-T cell therapies targeting solid tumor resistance mechanisms
  • 5.2. Innovations in non-viral genome editing platforms for scalable cell therapy manufacturing workflows
  • 5.3. Emerging off-the-shelf natural killer cell therapies for rapid immuno-oncology treatment response
  • 5.4. Integration of automated closed system bioreactors to reduce production costs in cell therapy scale-up
  • 5.5. Regulatory harmonization initiatives between FDA and EMA for expedited cell therapy market authorizations
  • 5.6. Application of artificial intelligence for predictive modeling of cell expansion and potency outcomes
  • 5.7. Development of personalized T cell receptor engineered therapies for targeting rare oncogenic antigens
  • 5.8. Use of induced pluripotent stem cells in allogeneic regenerative treatments for neurodegenerative diseases
  • 5.9. Strategic collaborations between biotech companies and CDMOs to strengthen global cell therapy supply chains

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell Therapy Technologies Market, by Offering

  • 8.1. Consumables
  • 8.2. Equipment
    • 8.2.1. Bioreactors
    • 8.2.2. Cell Analyzers
  • 8.3. Software & Services
    • 8.3.1. Data Management
    • 8.3.2. Quality Control

9. Cell Therapy Technologies Market, by Therapy Type

  • 9.1. Allogeneic Cell Therapy
    • 9.1.1. Dendritic Cells
    • 9.1.2. Induced Pluripotent Stem Cells
    • 9.1.3. Natural Killer Cells
  • 9.2. Autologous Cell Therapy
    • 9.2.1. Hematopoietic Stem Cells
    • 9.2.2. Mesenchymal Stem Cells
    • 9.2.3. T-Cells
  • 9.3. Gene-Modified Cell Therapy
    • 9.3.1. CAR-T Cell Therapy
    • 9.3.2. TCR (T-Cell Receptor) Therapy

10. Cell Therapy Technologies Market, by Manufacturing Process

  • 10.1. Cell Culture
    • 10.1.1. 2D Culture Systems
    • 10.1.2. 3D Culture Systems
  • 10.2. Cell Expansion
    • 10.2.1. Adherent Culture
    • 10.2.2. Suspension Culture
  • 10.3. Cell Separation
    • 10.3.1. Fluorescence-Activated Cell Sorting
    • 10.3.2. Magnetic-Activated Cell Sorting

11. Cell Therapy Technologies Market, by Delivery Method

  • 11.1. Ex vivo
  • 11.2. In vivo

12. Cell Therapy Technologies Market, by Application

  • 12.1. Cardiovascular Disease
    • 12.1.1. Ischemic Heart Disease
    • 12.1.2. Peripheral Artery Disease
  • 12.2. Musculoskeletal Disorders
    • 12.2.1. Osteoarthritis
    • 12.2.2. Rheumatoid Arthritis
  • 12.3. Neurodegenerative Diseases
    • 12.3.1. Alzheimer's Disease
    • 12.3.2. Parkinson's Disease
  • 12.4. Oncology
    • 12.4.1. Hematological Cancer
    • 12.4.2. Solid Tumors
      • 12.4.2.1. Breast Cancer
      • 12.4.2.2. Lung Cancer
      • 12.4.2.3. Prostate Cancer

13. Cell Therapy Technologies Market, by End User

  • 13.1. Biopharmaceutical Companies
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals
  • 13.3. Research Institutes
    • 13.3.1. Government Research Centers
    • 13.3.2. University Academics

14. Cell Therapy Technologies Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cell Therapy Technologies Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cell Therapy Technologies Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Allogene Therapeutics Inc.
    • 17.3.2. Atara Biotherapeutics, Inc.
    • 17.3.3. Century Therapeutics, Inc.
    • 17.3.4. Charles River Laboratories International, Inc.
    • 17.3.5. Gamida Cell Ltd.
    • 17.3.6. GE HealthCare
    • 17.3.7. Gilead Sciences, Inc.
    • 17.3.8. Johnson & Johnson Services, Inc.
    • 17.3.9. Novartis AG
    • 17.3.10. Sartorius AG
    • 17.3.11. Takara Bio Inc.
    • 17.3.12. Takeda Pharmaceutical Company Limited
    • 17.3.13. Thermo Fisher Scientific Inc.
    • 17.3.14. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREA